Last updated: February 24, 2026
What is NDC 33342-0139?
NDC 33342-0139 is the code assigned to Voretigene Neparvovec (brand name Luxturna), a gene therapy developed by Spark Therapeutics as a treatment for inherited retinal disease caused by confirmed biallelic mutations of the RPE65 gene.
Market Size and Epidemiology
Target Population
The therapy targets patients with confirmed RPE65 mutation-associated retinal dystrophy, a subset of inherited retinal diseases.
- Estimated prevalence: 1 in 200,000 individuals globally.
- U.S. prevalence: roughly 2,000 to 3,000 patients eligible.
- Key markets: United States, European Union, Japan, Canada.
Patient Identifiability
Diagnosis requires genetic testing with confirmation of RPE65 mutations, limiting rapid penetration.
Current Treatment Landscape
No approved pharmacological treatments for these inherited retinal diseases exist pre-gene therapy, leading to high unmet need.
Market Dynamics
Launch and Adoption
Luxturna launched in December 2017, with initial high costs and strict eligibility criteria. Adoption has been gradual, constrained by:
- High treatment costs.
- The need for specialized centers.
- Limited awareness among physicians and patients.
Competitive Landscape
Currently, no direct competitors exist with approved gene therapies targeting RPE65 mutations. Investigational pipeline remains sparse, with no immediate entrants.
Pricing Strategies
Spark Therapeutics set the list price at approximately $850,000 per eye in the U.S. in 2017, a figure that has faced scrutiny due to high upfront costs.
Pricing components:
- Cost for both eyes: approximately $1.7 million.
- Reimbursement challenges: insurance coverage variability, high initial out-of-pocket costs.
Reimbursement and Payer Strategy
Payers increasingly demand outcomes-based agreements.
- Indications to limit coverage to confirmed bilateral mutation-positive patients.
- Negotiated discounts and payment plans have emerged.
Price Projection and Future Trends
| Year |
Estimated Avg. Price (per eye) |
Total Market Penetration |
Estimated Revenue (for both eyes) |
| 2023 |
$850,000 |
50% of eligible patients |
$850 million |
| 2025 |
$700,000 |
70% of eligible patients |
$1.2 billion |
| 2030 |
$600,000 |
80% of eligible patients |
$1.6 billion |
Assumptions:
- Price reductions driven by market size expansion and payer negotiations.
- Growth in diagnosed patients due to increased awareness.
- Expansion to other indications that involve RPE65 mutations.
Risks and Challenges
- Pricing pressure: Payers may push for discounts, impacting revenue.
- Manufacturing constraints: The complexity of gene therapy production limits supply.
- Regulatory hurdles: Approvals for additional indications or markets.
- Long-term efficacy: Limited data beyond 5 years could influence market confidence.
Key Geographical Variations
- The U.S.: highest adoption, pricing, and reimbursement pressures.
- EU: national reimbursement policies vary, with some countries negotiating discounts.
- Japan and Canada: emerging markets with growing acceptance.
Conclusions
Luxturna's revenue prospects depend on widening patient identification, expanding geographic access, and negotiating sustainable reimbursement. Price reductions are likely as market volume increases and biosimilar or competing therapies are developed.
Key Takeaways
- NDC 33342-0139 (Luxturna) primarily treats RPE65 mutation-linked retinal dystrophy.
- The global small patient population limits total revenue but high prices sustain margins.
- Market growth depends on diagnosis rates and payer acceptance.
- Price projections anticipate reductions over time to broaden access and increase volume.
- Risks include reimbursement volatility, manufacturing capacity, and long-term data uncertainty.
FAQs
1. What factors influence the pricing of Luxturna?
Pricing is influenced by manufacturing costs, the small patient population, reimbursement negotiations, and market competition potential.
2. How many patients are eligible for Luxturna?
Approximately 2,000–3,000 in the U.S. with confirmed RPE65 mutations.
3. What are the main barriers to market expansion?
Diagnosis delays, high upfront costs, limited specialized centers, and reimbursement policies.
4. Are there any competitors for this therapy?
No approved competitors currently exist; the pipeline is limited.
5. How might prices change in the next five years?
Prices are expected to decline from around $850,000 per eye to approximately $600,000 as volume increases and market acceptance improves.
References
- U.S. Food and Drug Administration. (2017). Approved Drug Products.
- Spark Therapeutics. (2021). Luxturna Prescribing Information.
- MarketWatch. (2022). Gene Therapy Market Size & Trends.
- EvaluatePharma. (2022). Gene Therapy Pricing and Market Outlook.
- GlobalData. (2023). Inherited Retinal Diseases: Market Analysis.
[1] U.S. Food and Drug Administration. (2017). Luxturna (voretigene neparvovec-rzyl) approval.
[2] Spark Therapeutics. (2021). Luxturna prescribing information.
[3] MarketWatch. (2022). Gene therapy market trends.
[4] EvaluatePharma. (2022). Price trends in gene therapy.
[5] GlobalData. (2023). Retinal diseases market analysis.
